On December 15, 2021, Aramis Biosciences, a clinical-stage immuno-ophthalmology biopharmaceutical company, announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including its lead product candidate, A197, a novel, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment of dry eye disease.

Wilson Sonsini Goodrich & Rosati represented Aramis Biosciences in the launch and Series A financing. The team includes partner Mark Solakian and associates Amanda Creedon and Tamara Labanowski.

For more information, please see Aramis Biosciences' press release.